Maternal Complications and Prescription Opioid Exposure During Pregnancy: Using Marginal Structural Models

Xuerong Wen (), Shuang Wang, Adam K. Lewkowitz, Kristina E. Ward, Erin Christine Brousseau and Kimford J. Meador
Additional contact information
Xuerong Wen: University of Rhode Island
Shuang Wang: University of Rhode Island
Adam K. Lewkowitz: Alpert Medical School of Brown University
Kristina E. Ward: University of Rhode Island
Erin Christine Brousseau: Alpert Medical School of Brown University
Kimford J. Meador: Stanford University

Drug Safety, 2021, vol. 44, issue 12, No 5, 1297-1309

Abstract: Abstract Introduction Prescription opioids are frequently used for pain management in pregnancy. Studies examining perinatal complications in mothers who received prescription opioids during pregnancy are still limited. Objectives The aim of this study was to assess the association of prescription opioid use and maternal pregnancy and obstetric complications. Methods This retrospective cohort study with the Rhode Island (RI) Medicaid claims data linked to vital statistics throughout 2008–2015 included pregnant women aged 12–55 years with one or multiple live births. Women were excluded if they had cancer, opioid use disorder, or opioid dispensing prior to but not during pregnancy. Main outcomes included adverse pregnancy and obstetric complications. Marginal Structural Cox Models with time-varying exposure and covariates were applied to control for baseline and time-varying covariates. Analyses were conducted for outcomes that occurred 1 week after opioid exposure (primary) or within the same week as exposure (secondary). Sensitivity studies were conducted to assess the effects of different doses and individual opioids. Results Of 9823 eligible mothers, 545 (5.5%) filled one or more prescription opioid during pregnancy. Compared with those unexposed, no significant risk was observed in primary analyses, while in secondary analyses opioid-exposed mothers were associated with an increased risk of cesarean antepartum depression (HR 3.19; 95% CI 1.22–8.33), and cardiac events (HR 9.44; 95% CI 1.19–74.83). In sensitivity analyses, results are more prominent in high dose exposure and are consistent for individual opioids. Conclusions Prescription opioid use during pregnancy is associated with an increased risk of maternal complications.

Date: 2021
References: View references in EconPapers View complete reference list from CitEc
Citations:

Downloads: (external link)
http://link.springer.com/10.1007/s40264-021-01115-6 Abstract (text/html)
Access to the full text of the articles in this series is restricted.

Related works:
This item may be available elsewhere in EconPapers: Search for items with the same title.

Export reference: BibTeX RIS (EndNote, ProCite, RefMan) HTML/Text

Persistent link: https://EconPapers.repec.org/RePEc:spr:drugsa:v:44:y:2021:i:12:d:10.1007_s40264-021-01115-6

Ordering information: This journal article can be ordered from
http://www.springer.com/adis/journal/40264

DOI: 10.1007/s40264-021-01115-6

Access Statistics for this article

Drug Safety is currently edited by Nitin Joshi

More articles in Drug Safety from Springer
Bibliographic data for series maintained by Sonal Shukla () and Springer Nature Abstracting and Indexing ().